Treatment options in irritable bowel syndrome

Best Practice and Research: Clinical Gastroenterology

Volumn 18, Issue 4, 2004, Pages 773-786

  Farthing, Michael J G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 HT antagonists and agonists; Anti depressants; Anti diarrhoeal agents; Anti spasmodics; Fibre; Irritable syndrome

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILANSETRON; CIMETROPIUM; DIPHENOXYLATE; HERBACEOUS AGENT; LAXATIVE; LOPERAMIDE; MEBEVERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEW DRUG; OTILONIUM BROMIDE; PIBOSEROD; PINAVERIUM BROMIDE; PREDNISOLONE; PROBIOTIC AGENT; SEROTONIN 1 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNINDEXED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COLITIS; COLON DISEASE; CONSTIPATION; DIARRHEA; DIET THERAPY; DISTRESS SYNDROME; DRUG DESIGN; DRUG TARGETING; HUMAN; HYPERSENSITIVITY REACTION; HYPNOSIS; INTESTINE FUNCTION DISORDER; INTESTINE INFECTION; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; MENTAL STRESS; META ANALYSIS; MOOD DISORDER; MUCUS SECRETION; PATHOPHYSIOLOGY; PSYCHOTHERAPY; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 4344630844     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.04.008     Document Type: Article

References (61)

1. Farthing M.J.G. Irritable bowel, irritable body, irritable brain? British Medical Journal 310 1995 171-175
2. Whorwell P.J. McCallum M. Creed F.H. et al. Non-colonic features of irritable bowel syndrome Gut 27 1986 37-40
3. Gomborone J.E. Gorard D.A. Dewsnap P.A. et al. Prevalence of irritable bowel syndrome in chronic fatigue Journal of the Royal College of Physics 30 1996 512-513
4. Mayer E.A. Collin S.M. Evolving pathophysiologic models of functional gastrointestinal disorders Gastroenterology 122 2002 2032-2048
5. Mayer E.A. The neurobiology of stress and gastrointestinal disease Gut 47 2000 861-869
6. Gwee K.A. Graham J.C. McKendrick M.W. et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea Lancet 347 1996 150-153
7. Gwee K.A. Leong Y.-L. Graham C. et al. The role of psychological and biological factors in post infective gut dysfunction Gut 44 1999 400-406
8. McKendrick M.W. Read N.W. Irritable bowel syndrome - post Salmonella infection Journal of Infection 29 1994 1-3
9. McKendrick M.W. Post Salmonella irritable bowel syndrome - 5 year review Journal of Infection 32 1996 170-171
10. Neal K.R. Hebden J. Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome; Postal survey of patients British Medical Journal 314 1997 779-782
11. Spiller R.C. Postinfectious irritable bowel syndrome Gastroenterology 124 2003 1662-1671
12. Gwee K.A. Collins S.M. Marshall J.S. et al. Evidence of inflammatory pathogenesis in post-infectious irritable bowel syndrome (abstr) Gastroenterology 114 1998 758
13. Spiller R.C. Jenkins D. Thornley J.P. et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome Gut 47 2000 804-811
14. Bose M. Nickols C. Feakins R. et al. A comparison of 5-hydroxytryptamine staining in enterochronomaffin cells between irritable bowel syndrome and other gastrointestinal disorders Gut 47 2000 210
15. Farthing M.J.G. Lennard-Jones J.E. Sensibility of the rectum to distension and the anorectal distension reflex in ulcerative colitis Gut 19 1978 64-69
16. Klein K.B. Controlled treatment trials in the irritable bowel syndrome: A critique Gastroenterology 95 1977 232-241
17. Drossman D.A. Whitehead W.E. Camilleri M. Irritable bowel syndrome: A technical review for practice guideline development Gastroenterology 112 1997 2120-2137
18. Akehurst R. Kaltenthaler E. Treatment of irritable bowel syndrome: A review of randomised controlled trials Gut 48 2001 272-283
19. Francis C.Y. Whorwell P.J. Bran and irritable bowel syndrome: Time for reappraisal Lancet 344 1994 39-40
20. Bijkerk C.J. Muris J.W.M. Knottnerus J.A. et al. Systematic review: The role of different types of fibre in the treatment of irritable bowel syndrome Alimentary Pharmacology and Therapeutics 19 2004 245-251
21. Efskind P.S. Bernklev T. Vatn M.H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome Scandinavian Journal of Gastroenterology 31 1996 463-468
22. Poynard T. Naveau S. Mory B. et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Alimentary Pharmacology and Therapeutics 8 1994 499-510
23. Poynard T. Regimbeau C. Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Alimentary Pharmacology and Therapeutics 15 2001 355-361
24. Whorwell P.J. Prior A. Feragher E.B. Control trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome Lancet ii 1984 1232-1234
25. Whorwell P.J. Prior A. Colgan S.M. Hypnotherapy in severe irritable bowel syndrome; Further experience Gut 28 1987 423-425
26. Guthrie E. A brief psychotherapy with patients with refractory IBS British Journal of Psychotherapy 8 1991 175-188
27. Guthrie E. Creed F. The difficult patient: Treating the mind and the gut European Journal of Gastroenterology and Hepatology 6 1994 489-494
28. Talley N.J. Owen B.K. Boyce P. Paterson K. Psychological treatments for irritable bowel syndrome: A critique of controlled treatment trials American Journal of Gastroenterology 91 1996 277-283
29. Jackson J.L. O'Malley P.G. Tomkins G. et al. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis American Journal of Medicine 108 2000 65-72
30. Gorard D.A. Libby G.W. Farthing M.J.G. Effect of a tricyclic anti-depressant on small intestinal motility in health and in diarrhea-predominant irritable bowel syndrome Digestive Diseases and Sciences 40 1995 86-95
31. Gorard D.A. Libby G.W. Farthing M.J.G. 5 hydroxytryptamine and human small intestinal motility: Effect of inhibiting 5-hydroxytryptamine uptake Gut 34 1994 496-500
32. Farthing M.J.G. Irritable bowel syndrome: New drugs and therapeutic horizons, In: Farthing M.J.G. Malfertheiner P. (Eds.). Basic Mechanisms of Digestive Diseases: The Rationale for Clinical Management and Prevention 2002 59-73 John Libbey Eurotext Paris
33. Farthing M.J.G. 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists Scandinavian Journal of Gastroenterology 26 1991 92-100
34. Farthing M.J.G. New drugs in the management of the irritable bowel syndrome Drugs 56 1998 11-21
35. Farthing M.J.G. Irritable bowel syndrome: New pharmaceutical approaches to treatment Bailliere's Clinical Gastroenterology 13 1999 461-471
36. Sanger G.J. 5-Hydroxytryptamine and functional bowel disorders Neurogastroenterology and Motility 8 1996 319-331
37. Bearcroft C.P. Perrett D. Farthing M.J.G. Post-prandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome Gut 42 1998 42-46
38. Houghton L.A. Whitaker P. Atkinson W. et al. Increased platelet storesof 5-hydroxytryptamine (5-HT) in female patients with diarrhoea predominant irritable bowel syndrome (IBS) Gastroenterology supplement 1 2001 A636
39. 3 receptors in small and large intestine Current Research in Serotonin 3 1998 99-104
40. 4 Receptors in the Brain and Periphery 1998 213-226 Springer Berlin
41. 3 receptor antagonist, in patients with irritable bowel syndrome Alimentary Pharmacology and Therapeutics 1993 175-180
42. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome Alimentary Pharmacology and Therapeutics 7 1993 543-551
43. 3 antagonism (ondansetron) Digestion 57 1996 478-483
44. 3 receptor antagonists in modulation of visceral hypersensitivity British Journal of Pharmacology 114 1995 558-562
45. Camilleri M. Nortcutt A.R. Kong S. et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial Lancet 355 2000 1035-1040
46. Barbehenn E. Lurie P. Wolfe S.M. Alosetron for irritable bowel syndrome Lancet 356 2000 2009
47. Camilleri M. Chey W.Y. Mayer E.A. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Archives of Internal Medicine 161 2001 1733-1740
48. Rabasseda X. Leeson P. Silvestre J. Castaner J. Cilansetron Drugs of the Future 24 1999 475-482
49. Camilleri M. Review article: Tegaserod Alimentary Pharmacology and Therapeutics 15 2001 277-289
50. Muller-Lissner S.A. Fumagalli I. Bardhan K.D. et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Alimentary Pharmacology and Therapeutics 15 2001 1655-1666
51. Novick J. Miner P. Krause R. et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation Alimentary Pharmacology and Therapeutics 16 2002 1877-1888
52. Kellow J. Lee O.Y. Chang F.Y. et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome Gut 52 2003 671-676
53. FDA talk paper, July 24, 2002. http://www.fda.gov/bbs/topics/ANSWERS/ 2002/ANS01160.html
54. Schoenfeld P. Systematic review: Incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials Alimentary Pharmacology and Therapeutics 19 2004 263-269
55. Pimental M. Chow E.J. Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome American Journal of Gastroenterology 95 2000 3503-3506
56. Pimentel M. Constantino T.A. Kong Y. et al. A 14-day elemental diet is highly effective in normalizing lactulose breath test in IBS Digestive Diseases and Science 49 2004 73-77
57. Niedzielin K. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome European Journal of Gastroenterology and Hepatology 13 2001 1143-1147
58. Quigley E. O'Mahoney L. McCarthy J. et al. Probiotics for the irritable bowel syndrome (IBS): A randomized, double-blind, placebo-controlled comparison of Lactobacillus and Bifidobacterium strains Gastroenterology 122 2002 A59 Abstract
59. Hamilton-Miller J.M.T. Probiotics in the management of irritable bowel syndrome: A review of clinical trials Microbial Ecology Health Diseases 3 2001 212-216
60. Dunlop S.P. Jenkins D. Neal K.R. et al. Spiller R Randomized, double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome Alimentary Pharmacology and Therapeutics 18 2003 77-84
61. Madisch A. Holtmann G. Plein K. Hotz J. Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled multi-centre trial Alimentary Pharmacology and Therapeutics 19 2004 271-279